Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate—Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adults

BACKGROUND: New influenza vaccines eliciting more effective protection are needed, particularly for the elderly who paid a large and disproportional toll of hospitalization and dead during seasonal influenza epidemics. Low (≤15 μg/strain) doses of a new plant-derived virus-like-particle (VLP) vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Pillet, Stéphane, Couillard, Julie, Trépanier, Sonia, Poulin, Jean-François, Yassine-Diab, Bader, Guy, Bruno, Ward, Brian J., Landry, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550445/
https://www.ncbi.nlm.nih.gov/pubmed/31166987
http://dx.doi.org/10.1371/journal.pone.0216533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550445/
https://www.ncbi.nlm.nih.gov/pubmed/31166987
http://dx.doi.org/10.1371/journal.pone.0216533

Ejemplares similares